Davis Polk advised Auris Medical Holding AG on its registered direct offering of 12,499,999 of its common shares and concurrent private placement of warrants to purchase up to 7,499,999 of the company’s common shares. The registered direct offering resulted in total gross proceeds of approximately $5.5 million.
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology. The company was founded in 2003 and is headquartered in Zug, Switzerland. The common shares of Auris Medical Holding AG trade on the Nasdaq Capital Market under the symbol “EARS.”
The Davis Polk capital markets team included partner Sophia Hudson and associates Pedro J. Bermeo and Jaryn S. Fields. The tax team included partner Kathleen L. Ferrell and associate Andrew Imber. Associate Jennifer Lin Ricci provided 1940 Act advice. All members of the Davis Polk team are based in the New York office.